deltatrials
Completed PHASE4 NCT01831934

Responses to Influenza Vaccine in Patients With Mitochondrial Disorders (MELAS)

Metabolic and Immune Responses to TIV in Patients With Mitochondrial Disease

Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Conditions MELAS Syndrome
Interventions Fluzone®
Updated 8 times since 2017 Last updated: Apr 25, 2017 Started: Sep 30, 2010 Primary completion: Dec 31, 2011 Completion: Mar 31, 2012

Listed as NCT01831934, this PHASE4 trial focuses on MELAS Syndrome and remains completed. Sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), it has been updated 8 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Change History

8 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE4

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE4

  3. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE4

  4. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE4

  5. Jan 2021 — Dec 2022 [monthly]

    Completed PHASE4

▶ Show 3 earlier versions

  1. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE4

  2. Jun 2017 — Jun 2018 [monthly]

    Completed PHASE4

  3. Jan 2017 — Jun 2017 [monthly]

    Completed PHASE4

    First recorded

Sep 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
  • Stanford University
Data source: Stanford University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Stanford, United States